OpGen, Inc. (OPGN)
After hours: 07:58PM EDT
Chart Events
Performance Outlook
| Previous Close | 2.0800 |
| Open | 2.0700 |
| Bid | 2.0100 x 3100 |
| Ask | 2.0300 x 3000 |
| Day's Range | 1.9800 - 2.0700 |
| 52 Week Range | 1.6300 - 4.3700 |
| Volume | 1,239,943 |
| Avg. Volume | 2,670,875 |
| Market Cap | 77.689M |
| Beta (5Y Monthly) | -0.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3580 |
| Earnings Date | Nov 09, 2021 - Nov 15, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
Fair Value
Related Research
- OpGen, Inc.Daily Spotlight: Argus' Favored Classes, SegmentsStocks slumped in September, as is often the case, but still maintain a sizable performance lead over bonds heading into a typically positive time of the year for equity investors; the fourth quarter. Our Stock-Bond Barometer is close to equally balanced between stocks and bonds for long-term investors. In other words, these asset classes should be near their normal weights in diversified portfolios. We have looked for large-cap companies with strong balance sheets and experienced management teams to be the leaders during the eventual recovery from COVID-19. This has played well, and now, with vaccines being distributed, small-cap risks are reduced. Our recommended exposure to small- and mid-caps is now 15% of equity allocation, in line with the benchmark weighting. U.S. stocks have outperformed global stocks over the trailing one- and five-year periods. We expect this to continue over the long term, given volatile global economic and currency conditions. That said, international stocks offer favorable near-term valuations, and we target 15%-18% of equity exposure to the group. Value has been a surprise leader in 2021. We anticipate that growth, led by Tech and Healthcare, will recover and outperform value, led by Energy and Materials, as long as interest rates remain low.RatingFair ValueEconomic Moat10 days agoArgus Research
- GlobeNewswire
OpGen Announces $15 Million Registered Direct Offering
ROCKVILLE, Md., Oct. 14, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 150,000 shares of convertible preferred stock and warrants to purchase up to an aggregate of 7,500,000
- Benzinga
44 Biggest Movers From Yesterday
Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary endpoints. Elmira Savings Bank (NASDAQ: ESBK) gained 68.2% to close at $22.70 after the company announced it would be acquired by Community Bank System. Mexco Energy Corporation (NYSE: MXC) rose 46.4% to settle at $16.97 after OPEC+ agreed to stay with an existing pact to increase
- American City Business Journals
Rockville biotech lands federal approval for superbug testing system
The diagnostic aims to help doctors recognize drug resistance early in infections to help inform treatment decisions.
